Sandoz Partner Samsung Bioepis Settles On Stelara In US
Partners Snag Third-Earliest Launch Date So Far For Biosimilar Ustekinumab
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
